Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001279569-17-001056
Filing Date
2017-05-15
Accepted
2017-05-15 09:15:37
Documents
8
Period of Report
2017-05-15

Document Format Files

Seq Description Document Type Size
1 FORM 6-K essa6k.htm 6-K 12811
2 Q2 FINANCIAL STATEMENTS - SIX MONTHS ENDED MARCH 31, 2017 ex991.htm EX-99.1 356149
3 GRAPHIC image_001.jpg GRAPHIC 61533
4 MD&A - SIX MONTHS ENDED MARCH 31, 2017 ex992.htm EX-99.2 233768
5 GRAPHIC small_logo.jpg GRAPHIC 2273
6 CEO CERTIFICATION ex993.htm EX-99.3 9318
7 CFO CERTIFICATION ex994.htm EX-99.4 9294
8 PRESS RELEASE DATED MAY 15, 2017 ex995.htm EX-99.5 47132
  Complete submission text file 0001279569-17-001056.txt   757592
Mailing Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5
Business Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5 (778) 331-0962
ESSA Pharma Inc. (Filer) CIK: 0001633932 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
Type: 6-K | Act: 34 | File No.: 001-37410 | Film No.: 17841550
SIC: 2834 Pharmaceutical Preparations